technology
kē jì
科技
Novo Nordisk
Nuòhé Nuòdé
诺和诺德
and / with
yǔ
与
OpenAI (AI company)
OpenAI
OpenAI
to reach / to conclude
dáchéng
达成
strategic
zhànlüè
战略
partnership / cooperation
hézuò
合作
in order to
yǐ
以
artificial intelligence
rén gōng zhìnéng
人工智能
to accelerate
jiāsù
加速
drug / medicine
yàowù
药物
research and development
yán fā
研发
Denmark
Dānmài
丹麦
pharmaceutical
zhìyào
制药
giant / major player
jùtóu
巨头
Novo Nordisk
Nuòhé Nuòdé
诺和诺德
with
yǔ
与
OpenAI
OpenAI
OpenAI
on (date marker)
yú
于
April 14th
4 yuè 14 rì
4月14日
to announce
xuānbù
宣布
to reach
dáchéng
达成
strategic
zhànlüè
战略
partnership
hézuò
合作
to cover / to encompass
hángài
涵盖
drug / medicine
yàowù
药物
research and development
yán fā
研发
manufacturing / production
shēngchǎn
生产
and / as well as
jí
及
commercial / business
shāngyè
商业
operations
yùnyíng
运营
entire chain / end-to-end
quán liàntiáo
全链条
the said
gāi
该
partnership
hézuò
合作
aimed at / with the goal of
zhǐzài
旨在
by means of / with the help of
jièzhù
借助
artificial intelligence
rén gōng zhìnéng
人工智能
to shorten / to reduce
suōduǎn
缩短
drug
yàowù
药物
from
cóng
从
research
yánjiū
研究
to
dào
到
clinical
línchuáng
临床
application / use
yìngyòng
应用
(possessive / modifier particle)
de
的
cycle / timeline
zhōuqī
周期
May 7, 2026 at 5:00 AM
Denmark
Dānmài
丹麦
pharmaceutical
zhìyào
制药
giant / major player
jùtóu
巨头
Novo Nordisk
Nuòhé Nuòdé
诺和诺德
on (date marker)
yú
于
April 14th
4 yuè 14 rì
4月14日
to announce
xuānbù
宣布
with
yǔ
与
OpenAI
OpenAI
OpenAI
to reach / to conclude
dáchéng
达成
comprehensive / full
quánmiàn
全面
strategic
zhànlüè
战略
partnership agreement
hézuò xiéyì
合作协议
according to / based on
gēnjù
根据
agreement
xiéyì
协议
OpenAI
OpenAI
OpenAI
(possessive / modifier particle)
de
的
technology
jìshù
技术
will
jiāng
将
(passive voice marker)
bèi
被
comprehensively
quánmiàn
全面
to integrate / to incorporate
zhěnghé
整合
into
zhì
至
Novo Nordisk
Nuòhé Nuòdé
诺和诺德
(possessive / modifier particle)
de
的
drug
yàowù
药物
research and development
yán fā
研发
manufacturing
zhìzào
制造
supply chain
gōngyìng liàn
供应链
and / as well as
jí
及
commercial
shāngyè
商业
operations
yùnyíng
运营
each / every
gè
各
link / stage
huánjié
环节
partnership / collaboration
hézuò
合作
(possessive / modifier particle)
de
的
core / central focus
héxīn
核心
goal / objective
mùbiāo
目标
lies in / is centered on
zàiyú
在于
by means of
jièzhù
借助
artificial intelligence
rén gōng zhìnéng
人工智能
to analyze
fēnxī
分析
complex
fùzá
复杂
datasets
shùjù jí
数据集
to identify
shíbié
识别
new / novel
xīnxíng
新型
candidate
hòuxuǎn
候选
drugs / compounds
yàowù
药物
thereby / so as to
cóng'ér
从而
significantly
dàfú
大幅
to shorten / to reduce
suōduǎn
缩短
R&D
yán fā
研发
cycle / timeline
zhōuqī
周期
this time / on this occasion
cǐ cì
此次
collaboration
hézuò
合作
also / furthermore
yì
亦
to cover / to encompass
hángài
涵盖
employees / workforce
yuángōng
员工
artificial intelligence
rén gōng zhìnéng
人工智能
literacy / capability
sùyǎng
素养
training
péixùn
培训
planned / scheduled
jìhuà
计划
by
yú
于
end of 2026
2026 nián dǐ
2026年底
before
qián
前
to complete
wánchéng
完成
full / comprehensive
quánmiàn
全面
deployment / rollout
bùshǔ
部署
in terms of background / contextually
bèijǐng shàng
背景上
Novo Nordisk
Nuòhé Nuòdé
诺和诺德
is currently facing
zhèng miànlín
正面临
from
láizì
来自
US
Měiguó
美国
competitor / rival
jìngzhēng duìshǒu
竞争对手
Eli Lilly
Lǐlái
礼来
(possessive / modifier particle)
de
的
intense / fierce
jīliè
激烈
competition
jìngzhēng
竞争
especially / particularly
yóuqí
尤其
manifested in / particularly in
tǐxiàn zài
体现在
body weight
tǐzhòng
体重
management
guǎnlǐ
管理
drugs
yàowù
药物
field / sector
lǐngyù
领域
the industry
yèjiè
业界
analysts
fēnxī rénshì
分析人士
to believe / to argue
rènwéi
认为
this
cǐ cì
此次
collaboration
hézuò
合作
could help
yǒu zhù yú
有助于
Novo Nordisk
Nuòhé Nuòdé
诺和诺德
in
zài
在
next-generation
xià yī dài
下一代
weight-loss
jiǎnféi
减肥
drugs
yàowù
药物
R&D
yán fā
研发
in terms of / aspect
fāngmiàn
方面
to regain / to reclaim
chóngshí
重拾
competitive
jìngzhēng
竞争
advantage
yōushì
优势